Can AbbVie Imbruv on this?

While the future of Imbruvica ibrutinib as a cancer treatment is yet to be writ, it has definitely paid to own a piece of the action along the way. The drug, which has generated a little over half a billion in sales so far, has generated at least $13.7 billion in cash for its current and erstwhile owners.

The question is whether the pixie dust will carry over to AbbVie Inc. (NASDAQ:ABBV), which last week agreed to acquire Imbruvica's current owner, Pharmacyclics Inc. (NASDAQ:PCYC), for $21 billion, including about $12.2 billion in cash and $8.8 billion in stock...